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1. Abstract 
 
 
Human Breast Cancer, despite improved treatment and surgical resection stakes 
millions of lives. Chemotherapy drugs provide an option for cancer treatment, but the 
complication arises when these drugs target nearly every quickly multiplying cells in 
the body. This, in turn also targets the non- carcinoma that is normal cells in the body of 
the patient, leading to various side-effects such as bleeding, low-immune response, hair 
loss, fatigue, nausea, hot flushes, mood swings, infertility, hormone- imbalance, to 
name a few. Moreover, very few of the chemotherapy drugs target metastatic cancer 
cells, making the relapse of cancer more accountable, and also difficult to treat 
metastatic cancer through chemotherapy drugs. Natural chemicals are gaining increased 
limelight in the field of cancer research, due to their increased bioavailability and non-
harmful nature.   Embelin is a type of quinone derivative anti - cancer drug. It occurs 
commonly in Embelia ribes Burm. f. (Primulaceae) fruit.  The therapeutic properties of 
Embelin include Anti – Diabetic, Anti – Inflammation, Anti – Bacterial, Anthelmintic, 
and Anti – Tumor. As immune – related body reaction, inflammation leads to generation 
of multiple regulatory cytokines, a key cellular cytokine TNFα.  TNFα generation is 
reported to perform pivotal functions in human pathologies such as inflammation, 
neuro-degeneration and cancer development.  Various studies have reported Embelin 
showing its anti- inflammatory activity by reducing TNFα.  TNFα is present as a cell-
membrane bound protein, proactive form TNFα (inactive form); the active unit of 
inactive proenzyme -TNFα is then secreted by the cell, followed by cleavage by 
enzyme termed as TACE (TNF – alpha Converting Enzyme).  Therefore, TACE is 
considered a key biomolecules for targeting inflammatory responses and progression of 
cancer. In this study, molecular dynamic studies and in – vitro experimental techniques 
were used to understand the efficiency of docking and biochemical effects on TACE of 
Embelin, its effect on breast cancer cell line characteristics.  I illustrate here that 
Embelin can prove as a promising negative regulator of TACE.  Moreover, in vitro 
experiments explained that it hinders invasive potential of cancer cells by down-
regulation of metastasis targets including MMPs, VEGF, mortalin, TGF-β and hnRNP-
K in human breast cancer cell lines.  
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2. Abbreviations 
 
 
BSA             :       Bovine Serum Albumin 
BRCA1        :       Breast Cancer 1 
BRCA2        :       Breast Cancer 2 
DMEM        :       Dulbecco's Modified Eagle Cell culture Medium 
DNA            :       Deoxyribonucleic Acid 
DMSO         :       Dimethyl sulfoxide 
ECL             :       Enhanced Chemiluminescence reagent 
FBS              :       Fetal Bovine Serum 
FGF-10         :      Fibroblast growth factor -10 
HSP              :       Heat Shock Proteins 
hnRNP-K     :        HNRNPK heterogeneous nuclear ribonucleoprotein K 
MMP            :        Matrix Metalloproteinase 
μL                 :        Micro – liter 
mL                :        Milli – liter 
mM               :        Milli – Molar 
μM                :        Micro – Molar 
PBS               :       Phosphate Buffered Saline 
PCR               :       Polymerase Chain Reaction 
PVDF            :       Poly Vinylidene Fluoride 
RNA              :       Ribonucleic acid 
SDS               :       Sodium dodecyl sulfate 
TGF-β           :       Transforming growth factor beta 
TACE           :        Tumor necrosis factor-alpha converting enzyme 
TNF-α           :       Tumor necrosis factor-alpha 
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3.  CHAPTER I 
 
 
 
 
 
General Introduction 
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Cancer 
 
 
Cancer defines a pathology where defected cells in the body multiply 
uncontrollably, which also capably form tumors in other body parts. Cancerous 
cells metastasize to distinct regions of patients’ body by circulating system and 
lymphatic systems. Cancer begins to harm the host’s health when the unhealthy 
cells multiply without control thus developing primary tumors (exceptionally, 
during leukemia where cancer hinders functioning of normal blood tissue due to 
development of large population of defected cells in blood).  
Tumors that generate and grow may cause trouble with functioning of multiple 
systems in the body, such as nervous, circulatory and digestive system by 
releasing hormones. Tumors that are confined to an area and exhibit limited 
growth are generally called as benign. More invasive or malignant tumors form 
when two requirements are fulfilled:   
1. A cancer cell manages to move to distant body locations using the circulatory 
or lymphatic systems, by damaging tissues that are healthy in a phenomenon 
termed invasion. 
2. The cancer cell survives, multiplies and grows, developing new blood vessels 
to meet the energy requirements by a process called angiogenesis. 
Metastasis can be explained as the process in which cancer cells transport 
through the circulatory or lymphatic system. Cancer cells possess an enhanced 
tendency to multiply extensively and the multiplication rate is independent to 
telomere length on DNA. (a division controlling mechanism in normal cells). 
The disease affects people at all ages, but the risk factor increases with age, due 
to the fact that DNA damage becomes more apparent in aging DNA.  
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Current Cancer Statistics  
 
 
Cancer accounts for majority of deaths worldwide. In the year 2012, the world 
witnessed approximately 14.1 million new cancer cases: out of which 7.4 million 
(53%) in males and 6.7 million (47%) in females, giving a female: male ratio of 
9:10. The World age – standardized incidence rate showed that there occurs 205 
new cases for every 100,000 men in the world, and 165 for every 100,000 
females. About 585,720 people, in the year 2014, were estimated to fall prey of 
cancer. Among men, prostate, lung, and colon cancers sum up to about half of all 
newly diagnosed cancers, with prostate cancer alone marking for about one in 
four cases. Women are mainly reported for breast, lung, and colon cancer, which 
accounts for most common among them. Cancer of  the breast alone is expected 
to marks for 29% of all new cancers cases among women. (Figure 1-1) 
 
 
Causes of Cancer 
 
Cancer occurs as a result of cells that multiply without control and accumulate in 
patients’ body. In general cases, healthy normal cells maintain a balanced path of 
growth, division, and programmed death. Apoptosis or Programmed cell death, is 
an important process and when this stops occurring in normal cells, cancer 
begins to form.  
Due to Mutations, cancer cells undergo unbalanced growth and division, if there 
is DNA damage which result in mutations to the genes involved in control of cell 
division. Key families of genes that regulate cellular division are oncogenes 
(which guide the cells to multiply) and tumor suppressor genes (which function 
to stop cells from multiplication).  
Due to exposure to Carcinogens or Cancer inducing agents, are a type of 
substances that are superiorly involved in DNA damage, promoting and 
enhancing cancer. Examples of carcinogens range from Asbestos, Arsenic  
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Tobacco, and radiations such as x-rays and gamma-rays, UV radiation from the 
sun, and also, compounds in car exhaust fumes.
1
 Carcinogens exposure to human 
bodies release free radicals. These free radicals damage cellular functioning in 
the cells, hindering their ability to function normally.  
Family history can be one more reason for cancer; Cancer can result from 
inherited genetic faults from members of same family. Chemical or toxic 
compound exposures can also lead to cancer occurrence. Chemicals such as 
Benzene, Asbestos, Nickel, Cadmium, Vinyl chloride, N-nitrosamines, tobacco 
or cigarette smoke contains multiple known potential carcinogenic chemicals and 
toxins. 
 
 
Mechanism of Cancer 
 
Cancer begins when cells in the host’s body start to multiply uncontrollably. 
There are various kinds of cancers, but they all begin because of uncontrolled 
development of abnormal cells. Cancer cells grow differently than the normal 
cells. Instead of undergoing death, cancer cells continue division to form new, 
abnormal cells. Cancer cells are also capable of invading other tissues, a trait 
normal cell don’t possess. Cells become cancerous due to presence of damaged 
DNA.  In normal cases, when DNA is damaged in the cell, it is mainly rapidly 
repaired or the cell undergoes death. In cancer cells, the damaged DNA is not 
repaired and they don’t die. Instead, the damaged cell continues making more 
damaged cells. This happens due to 2 major mutations occurring in the two very 
important classes of gene, the oncogenes and the tumor-suppressor genes.
2
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Tumor – suppressor genes and Oncogenes 
 
Tumor – suppressor genes control cellular division and inhibit tumor growth and 
development. In most cancers, these genes lose their fuctioning, therefore thus 
enhancing cancer cellular proliferation as the regulators of cell division are not 
functional any more. During year 1971, Scientist Alfred Knudson explained the 
mechanism behind retinoblastoma development which requires 2 essential 
mutations in the Rb tumor – suppressor gene. Very prominent deletions of 
chromosome 13q14 were discovered in some retinoblastoma, bringing highlight 
that Rb gene inactivation initiates tumor growth and progression. 
The 2
nd
 major tumor – suppressor gene that discovered: p53, also frequently 
inactivated in a wide range of human cancers, including lymphomas, sarcomas, 
carcinomas of many tissues, including colon, lung, and breast and leukemia. 
Overall, mutations of p53 play a major role in development of more than 50% of 
cancers, exhibiting it as the most vulnerable target of genetic alterations in 
human malignancies.
3
 
Like p53, PTEN and INK4 tumor suppressor gene are also very commonly 
exposed to mutations in most cancers, such as, melanoma, prostate and lung 
cancer. Inherited mutations of 2 more tumor suppressor genes, BRCA1 and 
BRCA2, holds capable in inherited cases of breast cancer. This marks for about 
10% of total breast cancer cases. Opposite to proto-oncogene, proteins coded by 
tumor suppressor genes prohibit cellular growth and promote apoptosis of 
cancerous cells. Deactivation of these genes results in growth of tumor by ruling 
out inhibitory proteins.
4
 
Studies on tumor viruses explained that certain genes (termed oncogenes) hold 
potential of stirring up cell transformation, thus bringing 1
st
 facts into molecular 
basis of cancer. But, most of cancers of human origin are not caused due to 
viruses and are mainly arises from different factors, eg. Chemical carcinogens 
and radiation. The main bridge between cellular oncogenes and viruses was 1
st
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obtained by analysis of highly oncogenic retroviruses. DNA obtained from 
human bladder carcinoma could effectively cause tumorigenic transformation in 
recipient mouse cells by in – vitro tissue culture, highlighting that human tumors 
possess a functionally active oncogene. These assays of gene transfer along with 
other techniques have resulted in detection of active oncogenes in human tumors 
of multiple types. The 1
st
 human oncogene identified was the human homolog of 
rasH oncogene of Harvey sarcome virus. 3 closely linked members of the ras 
gene family (rasH, rasK, and rasN) are oncogenes that are most commonly 
encountered in human tumors. These genes are found in average of 20% of all 
human malignancies, including 25% of lung carcinomas and 50% of colon 
cancer. 
Oncogenes such as Ras do not occur normally in cells; however, they are 
developed in cancerous cells due to alterations that happen while tumor 
development. Ras oncogene is different than proto – oncogenes by single amino 
acid substitutions that occur as point mutations at significant positions. 1
st
 such 
mutation found was a change of Valine for Glycine at position 12. Other amino 
acid changes at position 12, 61 and 13, are also discovered in ras oncogene of 
tumors of human origin. Study in animal systems depicted that mutations which 
convert ras proto-oncogenes to oncogenes are caused by chemical carcinogens, 
bringing a direct link between the mutagenic action of carcinogens and cell 
transformation.
5
 
The gain-of-function of oncogenes and loss-of-function of tumor-suppressor 
genes are major steps in tumor initiation and progression. Collective damage to 
multiple genes eventually leads to enhanced cell division, invasiveness, and 
metastatic potential that are main features of cancer cells. 
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Treatments for Cancer 
4 general methods for treatment of cancer include: surgery, chemotherapy, 
radiation therapy, and immunotherapy/biologic therapy. Surgery: mainly 
performed to remove cancerous tissue or as much of the as possible tumors. It is 
usually done together with chemotherapy or radiation therapy. Chemotherapy: 
utilizes anti-cancer drugs to eliminate cancer cells. Unlike surgery, chemotherapy 
effects the whole body of the patient, and not just a specific part. Its mechanisms 
involve killing fast rate diving cells. As other types of cells in human bodies also 
multiply at high rates, therefore, leading to occurrence of multiple side effects 
like fatigue, hair loss, and an ulcers. This kind of therapy is mainly given in the 
form of tablets or by intravenous injections (IV). Radiation Therapy: used to 
shrink the size of tumors and/or eliminate cancer cells. It functions by destroying 
cancer cell's DNA, making it unable to divide. Cancer cells are very sensitive to 
radiation and typically die when exposed. Nearby healthy cells are usually 
damaged as well in the process, but in most cases recover completely. Biological 
or Targeted Therapy: used for drugs whose mechanism of action focus on 
targeting unique characteristics of cancer cells. Few targeted therapies work by 
hindering the survival processes of tumors that allow tumors to multiply and 
develop. Other kinds cut out the blood – oxygen supply to cancerous tissue, 
causing it to starve and die because of a lack of nutrients. Immunotherapy: 
works to develop immune system to fight against the tumor. Local 
immunotherapy involves injecting a treatment into a specific area, for example, a 
mechanism to cause inflammation that makes tumor shrink. Systemic 
immunotherapy involves administering an agent into the whole body that can 
target shrink tumors throughout the body. Autologous stem Cell 
Transplantation or Bone Marrow Transplant: a most common method to treat 
leukemia and multiple myeloma. Bone marrow, which is made up of 
hematopoietic stem cells, is a spongy substance found inside large bones in the 
body, such as the femur, hips and ribs.  
10 
 
Breast Cancer 
 
 
A large number of breast cancer cases are detected each year, making it stake 
multiple lives. (Figure 1-2) 
2 medicines for the women with very high breast cancer risk are – raloxifene and 
tamoxifen. Raloxifene is seen to lesser side effects, such as blood clots and uter-
ine cancer. Moreover, it used only in post – menopausal women. Tamoxifen, on 
the other hand is a drug used for several past, but it may lead to development of 
unwanted side – effects. Some common side – effects caused by tamoxifen are 
menstrual changes, redness of the face, neck, arms and occasionally, upper chest, 
irregular or absent periods, rattling breathing, decrease in the amount of urine, 
swelling of the fingers, weight gain or loss feeling of warmth, skin changes, 
stopping of menstrual bleeding, hands, feet, or lower legs, white or brownish 
vaginal discharge, troubled breathing at rest. Localized surgery such as those of 
conserving the breast or mastectomy (surgical removal of the breast). Lymph 
nodes from the Underarm area are usually checked in the process to analyze the 
degree of spread of cancer. Breast cancer therapies may include chemotherapy 
(before or after surgery), radiation, aromatase inhibitors, hormone therapy or 
targeted therapy.  
 
Metastasis 
 
The process of metastasis holds great value in understanding cancer as majority 
of cancer related deaths account due to systemic spread of cancer rather than the 
localized tumor. Cancer patients with non – spread cancers show significantly 
higher rate of survival than patients with metastatic cancers. Latest research 
reports bring highlight on the idea that cancer metastasis can be an early event 
and the chances of metastasized cancer are almost 60% during diagnosis. 
Thereby, advanced treatment strategy that can target both cancer cells in the 
primary tumor as well as the disseminated cancer cells would be really helpful. 
7
 
Moreover, every patient, with or without metastasized cancer holds an equal 
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amount of risk for the disease to spread out. In an average, almost 1/3 of women 
whose lymph nodes were negative are likely to develop secondary site tumors. In 
the process of metastasis, to successively develop a secondary location, 
cancerous cell undergoes multiple steps until it forms a medically detectable 
tumor. A cancer cell must invade and damage surrounding tissues, reach and 
survive in the body circulation to reach to distant sites and form micro-
colonies.
8,9
(Figure 1-3) 
Due to many steps to overcome in this process, therefore, metastasis at an overall 
rate is a process with multiple loop-holes. 
7
 As, the failure to successfully 
complete any of the multi-step process will lead to failure in the development of 
secondary colonies. Thus, bringing in some hope to beat the process of 
metastasis. 
 
Significance of cellular Hsp.s in cancer  
 
The generation of resistance for therapies, such as those of chemotherapy and 
hormonal therapy, makes the number of deaths by cancer even more higher. 
Exposing the cancer tissues to anti cancer therapies leads to development of 
cellular stress, which is biochemically regulated by a family of proteins, called 
Heat Shock Family Proteins (Hsp.s), In normal situations, Heat Shock Proteins 
deal together with multiple small proteins to help in protein folding, and recover 
the cell from stress, therefore, enhancing survival of cell.
10
 These proteins also 
inhibit functioning of apoptosis related proteins by interacting with them, and 
thus preventing apoptosis. 
Heat shock family proteins (HSPs) were initially found in the year 1962. These 
proteins are superiorly conserved in all kind of living organisms and are 
functional when cell encounters any kind of stress. These proteins are ubiquitous 
in nature and are identified as cyto-protective molecular chaperones.
11
 4 major 
heat shock families of proteins are HSP70, HSP60, , HSP90 and HSP27. These 
proteins play a key role in protein transport even during normal cellular 
12 
 
conditions. However, a requirement for these Heat Shock Proteins skyrockets 
when cell encounters some kind of stress to protect the cells.  
HSP70 & HSP27 makeup the most significantly regulated molecular chaperones 
when cell encounters stress. They are excessively generated in cancerous cells 
and help in maintaining chemo-resistance. Increased amounts of HSP70 family 
proteins exhibited to be essential for protecting the cancer cells, while a loss of 
HSP70 in tumor cells population led to extensive cellular death or apoptosis. A 
major regulatory protein involved in maintaining cellular survival is Mortalin or 
mthsp70 or PBP74 or Grp75.
10
 
 
Mortalin: function and significance in cancer progression & 
cancer metastasis 
Mortalin is a key regulator of the Heat Shock Family 70 (Hsp70) proteins. This 
was for the first time studied in fractions of cytoplasm from fibroblastic cells of 
normal mouse. 
10-12
 
Moreover, this protein was seen to exhibit different cellular localization in case 
of normal cells and in case of immortal cells. cDNA study explained presence of 
2 types of mortalin in a cell, Mortalin 1 (mot-1) that was localized throughout the 
cytoplasm in the cell, while mortalin-2 (mot-2) that was present around the 
nucleus in cells. It was seen that mortalin-1 and mortalin-2 were different by two 
amino acids, and by that difference they have completely contrasting biological 
activity in the cells. When the mortlin-1 cDNA was transfected to NIH 3T3 
cancer cell line, the presence of this protein led to senescence of cells.   
Whereas, when the cDNA of mortalin-2 was incorporated in the same cancer 
cells, a perinuclear protein that resulted, which enhanced the malignancy of cell, 
increased their survival and lifespan.
13,14
 
Every cell of mammalian origin is known to possess the protein mortalin, 
depicting some kind of essential survival function of the protein.
15
 Making it 
explainable that over- expression of this chaperone results in gain of extensive 
survival efficiency in cells, making them immortal. Upon studying the 
13 
 
expression levels of mortalin in both normal and tumor cells exhibited its 
significant upregulation in case of tumor cells. Other than this, Mortalin is also 
seen to interact with its binding partner p53, leading to suppression of its tumor 
inhibiting function, and thus inhibiting tumor growth. 
16-18
 
Over the past several years of research, mortalin has been shown to be a binding 
partner to different proteins involved in apoptosis or cell death and halt their 
specific function to enhance cell survival. 
19,20
 
Besides p53, Mortalin has been to shown to interact with apoptosis related 
proteins, hTERT,
21
 Bcl-2
22
 and Bcl-xL and inhibit cellular apoptosis and 
therefore, promote cell survival.
23,24
 Mortalin has also been identified to be 
localized in the nucleus, and this nuclear mortalin was shown to promote 
enhanced carcinogenesis and increased metastatic ability in cancer cells. Very 
recently, Mortalin role in the Parkinson’s disease has also been highlighted. 
Bringing highlight to mortalin functioning in a cancer cell brought light on it as 
an important target for cancer therapy. 
25
 
 
 
Targeting Mortalin by anti-mortalin molecules 
 
 
The above knowledge makes mortalin a good target for studying potential 
anticancer drugs.
26
 Based on this idea, several anti-mortalin drugs are being 
studied.  
MKT-077 is a chemical mortalin inhibitor. It’s a type of rhodacyanine dye that 
selectively kills to cancer cells. Moreover, this drug was seen to cause arrest of 
growth in cancer cells, which also resulted in a shift in the staining pattern of 
mortalin, which is one of the major features of normal cells. Cytoplasmic 
localization of p53 could possibly be a method of p53 inactivation in some 
tumors. Mortalin is known to bind to p53 and hold it in the cytoplasm, Thereby, 
targeting mortalin by some kind of anti – mortalin molecules cold help release 
p53 to the nucleus, thereby, initiating tumor suppressor functions of p53. Use of 
specific mortalin small interfering - RNA has lead to yield similar results.
29,30
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Therefore, a need to investigate more anti-mortalin molecules, majorly the ones 
that will be less toxic, could help to prove better anti-cancer potents. 
Complications in anticancer drugs and the need for natural 
anti-cancer therapy 
Since ancient times, plant derived natural products have been of immense 
importance in healing various kinds of diseases. The need for a better anti-cancer 
drug, brings focus on the development of useful medicine from mother nature. 
The vast diversity of nature derived compounds and their promising potential 
have brought plant – derived components to a new height. The usage of these 
compounds promises relatively very few side – effects. Moreover, these 
compounds are more efficient in treating a variety of diseases and can prove as 
wide – spectrum drugs.  
The main hurdles in the current available treatments against the cancer lie in its 
non- specificity, increased costs, re-occurrence of cancer and many more. The 
current available drugs mainly emphasize on killing the cancer cells, which in a 
way targets every rapidly dividing cell in the body. This leads to weak immune 
system and low immune response, making a patient more vulnerable to other 
side infections. Moreover, killing of most rapidly dividing cell in the body 
renders the patient different side-effects such as nausea, hair-loss, fatigue, etc. 
Despite these reasons, the most important being the recurrence of cancer in the 
patients by the low-efficiency of the drugs to target metastasized cancer or the 
metastatic cancer cells. These reasons leave us to seek for some safer and 
economic treatment option for cancer, which could beneficially also target highly 
invasive cancerous cell. 
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Research Objectives 
 
Cancer marks as a deadly disease, which is one of the major causes of mortality 
across the world. Cancer is caused when the cells in the patient’s body begin to 
divide controllably. The statistics for cancer begin to grow, despite the 
therapeutic advances. 
Cancer is caused by a variety of different causes, ranging from age, family 
history to exposure to carcinogens. Biochemically, cancer is caused when there is 
imbalance in the functioning to 2 types of genes, the oncogenes and the tumor-
suppressor genes. A loss – of –function in tumor-suppressor genes and a gain-of-
function in oncogenes leads to imbalance of growth stimulatory signal leading to 
uncontrolled cell division.  
Today, a variety of treatments based on the stage of cancer are available. These 
treatments are either used alone or in conjunction.  
Most cancer patients that have primary cancers show better response rate than 
the ones whose cancers have already metastasized. Thereby, advanced treatment 
strategy that can target both cancerous cells in the primary tumor as well as the 
disseminated cancer cells would be really helpful.  
Another reason for the failure of maximum anti-cancer drugs accounts for the 
development of chemo-resistance in the cancer cells. This is a common 
phenomenon as treatment of cancer induces a state of stress in the cancer cells 
from which to survive them, they begin to over-express a variety of stress 
proteins. These stress proteins help the cell to fight against the stress induced by 
chemical drugs, promote cell survival. One of the most common family of stress 
proteins is heat shock family 70 proteins (hsp70) that are the first ones to be 
expressed. These proteins act as a guardian to the cell by promoting cell survival. 
Mortalin is a hsp70 family protein, it is highly abundant in cancer cells and has 
been widely demonstrated for its cell survival abilities by enhancing growth of 
cancer cells, promoting metastasis, causing drug resistance, inactivating p53 and 
in halting the process of apoptosis. Based on these observations, mortalin is 
considered to be a therapeutic target against  
16 
 
 
 
cancer. Anti-mortalin molecules could therefore prove of great importance in 
developing anti – cancer drug.31,32  
Moreover, the current available drugs mainly emphasize on killing the cancer 
cells, which in a way targets every rapidly dividing cell in the body. This leads to 
enhanced side –effects of the cancer treatment to the patient’s health and causing 
various health problems such as weight loss, weak immune system, fatigue, 
diarrhea, pain, blood disorders, sores in the mouth and throat, nausea, vomiting, 
hair loss, nervous system effects such as weakness or numbness in the hands 
and/or feet, Loss of balance, tingling, sore, burning, tired, or achy muscles, 
trembling or Shaking or Stiff neck, headache, walking problem, visual problems, 
memory loss to name a few. 
All these above factors, illuminate a need for the search and development of 
more safe, non-harmful, more-specific anti-cancer drugs. 
Since, herbal medicines have always been used for the past hundreds of years 
and as of now, the incidence of cancer was very low back at the ancient times, 
giving us a hint that these herbs may also have an answer for developing a safe 
anti-cancer drug.  
Several plants have been well known for their medicinal properties in the 
traditional medicinal system. Some of these plants are also known to possess 
anti-cancer properties. However, much study on the mechanism of the 
effectiveness of these drugs has not been done so far. As the side effects and 
loopholes of the conventional drugs are being illumination, more and more focus 
is shifting on the nature based drugs for the development of a safer and healthier 
society.  
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Based on the above information and the needs in the development for new better 
and safer drugs for breast cancer, we developed a research plan, which would 
target the following aspects for formulation of a potential candidate for breast 
cancer therapy, 
 New candidate that would be better than the current conventional drugs. 
 It would be safe to the patient and would not be an inducer of several 
toxic side effects. 
 It could target both cancerous cells in the primary tumor as well as the 
metastatic cancer cells that have been disseminated or are in the process 
of dissemination. 
 It could over come the barrier of chemo resistance by targeting the heat 
shock family proteins that are specifically known to enhance cell survival 
ability by inducing chemo resistance. 
 And, finally, to study the mechanism of action of such an anti-cancer 
potential drug. 
Based on these criteria, we thought, it would be worthwhile to study the 
expression levels of mortalin when the cells are treated with the potential 
candidates for the study. Mortalin was used as a selection marker protein as its 
role in imparting cell survival properties; induction of highly metastatic 
properties, and in the enhancement of cancer has been well documented, mainly 
by its binding activity with the tumor – suppressor protein, p53 and thus inducing 
its inactivation. 
33,34
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Embelin 
 
Embelin is the main active component, which is a type of benzo-quinone, 
derived from the fruits of an Indian herbal plant Embelia ribes. (Figure 1 – 4) 
Embelia ribes, generally called as False Black Pepper or White-flowered 
Embelia, is a species in the Primulaceae. Nicolas Laurens Burman originally 
described it in his 1768 publication, Flora Indica. Susruta described the fruits of 
this plant as Anthelmintic, Alterative and Tonic and recommended its use along 
with liquorice root for the purpose of strengthening the body and avoiding aging 
effects. 
Embelia ribes is a scandent shrub with thin branches and elliptic-lanceolate and 
gland-dotted leaves. The plant possess Embelin, quercitol, and fatty ingredients; 
an alkaloid, christembine, a resinoid, tannins and minute quantities of a volatile 
oil. Embelin occurs as golden yellow needles insoluble in water, while soluble in 
alcohol, chloroform and benzene. It is known to be effective against tapeworm. 
Embelin and its salts possess anti-inflammatory potential. Fruits in the dried 
form possess medicinal properties such as Anthelmintic, Carminative, Astringent 
and Stimulant. Its usage in India as Anthelmintic and Ascariasis is since ancient 
times. Fruits in the dried form are used against fevers and for chest and skin 
diseases. The fruits also possess Anti – bacterial property. Plant is known to heal, 
bronchitis, migraine, asthma, fever, skin diseases, flatulence, weakness, 
constipation, cough, intestinal worms.  
Embelia root bark is acrid, astringent, anthelmintic, antifertility, anti-estrogenic, 
carminative, digestive, laxative, soothing, stimulant, stomachic, and thermogenic.  
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4.  CHAPTER II 
 
 
 
Initial Screening  
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Abstract 
 
Cancer is a division of diseases characterized by uncontrolled cell growth. This 
happens mainly due to loss-of-activity of tumor-suppressor genes and enhanced 
activity of oncogenes. Due to increased occurrence of permanent and impermanent 
side effects caused by the current cancer therapy, there is a constant search for better 
anti-cancer drugs in order to provide significant relief to the cancer patients in a non 
– harmful manner. 
Heat shock proteins, are known to be frequently over-expressed in a majority of 
cancers, owing to the enhanced survival and induced chemo-resistance in cancer 
cells. Mortalin is a key heat shock protein and is considered to be a key therapeutic 
target against cancer. 
In this chapter, we select a potential anti-cancer therapy candidate, Embelin, for our 
further study, based on its ability to effectively decrease cellular levels of Mortalin 
in human breast cancer cell lines. 
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Introduction 
 
 
Current available cancer therapies mainly focus on killing cancer cells. Since, these 
cancer drugs do not specifically target cancer cells, they at the time of action, also 
target the rapidly multiplying normal cells. This mechanism of action leads to 
accountability of various side effects by a cancer patient. Some of these side effects 
are impermanent and disappear over a period of time. Whereas, many of other side 
effects caused by these drugs damage a person’s health in an irreparable manner, by 
causing a permanent damage.  
These highlights over the current cancer treatment, have lead to the initiation of a 
search for finding better anti-cancer drugs. The search of these drugs today targets 
on focusing on other mechanism of targeting the cancer progression, besides using 
the traditional mechanism of targeting cancer cells by killing. Upon finding a 
suitable anti-cancer drug, encountering chemo-resistance is another critical aspect 
that needs to be dealt with. 
Several biomolecules are over-expressed in cancer cells and these biomolecules 
further lead to enhanced cell survival ability of cancer cells. One such class of 
biomolecules which are significantly expressed in cancer cells are heat shock 
proteins or HSP.s. One of the key player in this family is Mortalin. The past decade 
of research has highlighted the importance of mortalin in enhancing cell survival 
ability and in enhancing the progression of cancer. Therefore, mortalin is considered 
to be a key therapeutic target against cancer. 
In this chapter, we perform screening of a variety of commercially available drugs 
and two nature derived compounds, for their anti-mortalin ability. Based on the 
effect of following drugs on Mortalin levels, we selected Embelin as a potential anti-
cancer candidate for our further study. 
 
 
 
 
22 
 
 
Materials and Methods 
 
 
Cells, Drugs and Cell Culture 
 
The breast cancer cells studied were: MCF-7 and MDA-MB-231. Human Breast 
Carcinoma – MCF-7 (Adenocarcinoma), MDA-MB-231 (Adenocarcinoma) were 
purchased from Japanese Collection of Research Bioresources (JCRB, Japan) 
Cell Bank. MCF-7 and MDA-MB-231 were cultured in the DMEM (Dulbecco’s 
Modified Eagle Medium) (Life Technologies, CA) that was supplemented with 
10% FBS (fetal bovine serum) at 37 °C, in a humidified incubator (5% CO2 and 
95% air).  
Embelin was obtained purified from Sigma Aldrich Co., Japan. Embelin stocks 
were then, made by dissolving the adequate amount of it in dimethyl sulfoxide 
(DMSO) to obtain 1 mM stocks. These 1 mM stocks were aliquoted into tubes 
and were preserved at -20°C for further use. Concentrations were made by 
diluting the 1mM Embelin stock to the complete cell culture medium (DMEM) 
that was used for each experiment. All biochemical and imaging assays were 
performed at sub-confluent (60–70%) cultures.   
 
Immunoblotting 
 
To identify the effect on expression level of proteins in effect to that of Embelin –
treatment, Immunoblotting technique was used. Cells that were priorly treated and 
not-treated with Embelin were prepared as protein lysates samples for loading in 
SDS – PAGE gels. Equal amounts of whole cell protein samples from control and 
treatment groups were seperated on 10% SDS-polyacrylamide gels, and transferred 
to PVDF membrane. The blots were incubated with the desired primary antibodies 
followed by their respective secondary antibodies. Anti β-actin antibody was used as 
internal loading control. Quantitation of western blots was done by ImageJ software 
(NIH, MA). 
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Immuno – cytochemical staining 
 
For immuno - fluorescence or immuno – cytochemical staining, cells were 
cultured in 12-well dish containing coverslips. Control and cells from treatment 
groups were fixed, and stained with primary and secondary antibodies of interest 
for the study. In this study, antibodies for Mortalin and p53 were used. 
Coverslips containing stained cells, were mounted and observed using Carl Zeiss 
microscope (Axiovert 200 M). 
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Results 
 
Embelin decreases the cellular expression levels of Mortalin  
 
To select a potential non – harmful anti- cancer drug candidate, a variety of different 
anti – cancer compounds, including commercially available compounds and two 
nature derived compounds are tested for their anti-mortalin ability.  
As seen by the immunofluorescence results, the nature derived compounds, Embelin 
and CAPE was seen to be very effective in reducing the cellular mortalin expression 
levels. A similar anti – mortalin effect was observed in both the human breast cancer 
cell lines, MCF7 (Figure 2 – 1) and in MDA-MB-231 (Figure 2 – 2). Their effect in 
reducing the cellular mortalin levels was seen to be better than Adriamycin, a drug 
known for it’s anti – cancer property.  
A similar reduction in the mortalin levels was observed by a different cellular 
experiment (Immunoblotting) (Figure 2 – 3) and also by the pixel calculation of 
these results (Figure 2 – 4). 
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Discussion  
 
Current available anti - cancer treatments are inefficient in specifically targeting 
cancer cells, thereby accounting for multiple side effects. Moreover, anti – cancer 
drugs can barely target metastatic or disseminated cancer cells, leading to re-
occurrence of cancer. Based on these insights, there is a constant search for a better 
anti-cancer drug.  
This study started with the idea to screen a potential anti- cancer drug candidate, 
which would be less harmful for the cancer patients.  
In this chapter, an initial screening of several potential candidates was performed by 
investigating their anti-mortalin ability. Mortalin is a heat – shock family protein 
and is known to be over expressed in cancers. Mortalin significantly imparts cell 
survival property to cancer cells, as the down – regulation of mortalin leads to 
enhanced cell death response.  
In the study conducted, Embelin, which is a plant compound, was observed to be 
very promising by its ability to reduce cellular mortalin levels. Moreover, its anti-
mortalin efficiency was seen to be better than Adriamycin, a drug commonly used 
during cancer chemotherapy. Although, Adriamycin is a very effective anti-cancer 
drug, its main drawback lies in its ability to cause life – threatening heart damage. 
Based on its ability to significantly reduce cellular mortalin levels, Embelin was 
selected for further investigation, as a potential anti – cancer candidate.  
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5.  CHAPTER III 
 
 
 
 
 
 
Cytotoxic effect of Embelin on 
Breast Cancer cells and their metastatic 
derivatives 
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Abstract 
 
 
Human Breast Cancer, despite improved treatment and surgical resection stakes 
millions of lives. Chemotherapy drugs provide an option for cancer treatment, 
but the complication arises when these drugs target all frequently multiplying 
cells in cancer pateint’s body. These, in turn also targets the non- carcinoma 
quickly multiplying cells of the patient, leading to various side-effects such as 
bleeding, low-immune response, hair loss, fatigue, nausea, hot flushes, mood 
swings, infertility, hormone- imbalance, to name a few. Moreover, very few of 
the chemotherapy drugs target metastatic cancer cells, making the relapse of 
cancer more accountable, and also difficult to treat metastatic cancer through 
chemotherapy drugs. Natural chemicals are gaining increased limelight in the 
field of cancer research, due to their increased bioavailability and non-harmful 
nature.   Embelin is a kind of benzo-quinone compound and is derived from 
fruits of an Indian herbal plant known as Embelia ribes Burm. f. 
(Primulaceae).  Embelin possesses various therapeutic properties such as 
Anthelmintic, Anti-Tumor, Anti-Diabetic, Anti-Bacterial and Anti-Inflammatory.  
Based on the known effectiveness of Embelin as a therapeutic agent, we decided 
to investigate Anti-cancer potential of Embelin. Since, Breast cancer accounts for 
millions of deaths worldwide, we selected an in-vitro experimental model of 
Human Breast Cancer cell lines. In this chapter, we explain results showing 
Embelin exhibits Anti-Cancer potential by inhibiting the proliferation activity of 
cancer cells. 
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Introduction 
 
 
Breast cancer accounts for millions of deaths worldwide, making it one of the 
deadly health problems to be dealt with. Despite the availability of a wide variety of 
treatments options for the disease, such as improved chemotherapy, hormonal 
therapy, and surgical resection, there is still a long way to conquer the deadly 
disease. One of the reasons for the failure of the effectiveness of the above 
treatments is the high ability of the breast cancer to metastasize.  
Metastasis is process in the stage of cancer in which cells in the primary tumor 
begin to detach themselves and move out of the tumor. After moving out from the 
original tumor site, many of cancer cells die and the remaining cancer cells travels 
to different locations of the body with the help of the blood circulation or the lymph 
nodes in the body. And, upon reaching to different favorable locations in the body, 
these cells began to divide in order to form micro-metastasis. Many of the these 
micro-metastasis are ruled out by the immune system of the body, however the ones 
that survive further divide uncontrollably leading to formation of secondary tumors. 
Metastasis or the Breast Cancer metastasis was initially thought to be a concluding 
stage in the progress of cancer. However, recent reports on metastatic breast cancer 
depict it as an early event during cancer growth, showing escape of cells to other 
body parts, in an early cancer stage such as ductal carcinoma in-situ (DCIS), making 
breast cancer an even more important issue to be dealt with. 
35,36
 Chemotherapy 
drugs provide an option for cancer treatment, but the complication arises when these 
drugs target quickly multiplying cells in the body. These, in turn also targets the 
non- carcinoma quickly multiplying cells in the body of the patient, leading to 
various side-effects such as bleeding, low-immune response, hair loss, fatigue, 
nausea, hot flushes, mood swings, infertility, hormone- imbalance, to name a few.  
Moreover, very few of the chemotherapy drugs target metastatic cancer cells, 
therefore leaving the metastatic cancer cells still healthy. This results into making 
the relapse of cancer more accountable, and also difficult to treat metastatic cancer 
through chemotherapy drugs. 
37
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Herbal plants that are known to have therapeutic properties are used since ancient 
times as a solution for different ailments and to help the mankind. Ayurveda or the 
Indian traditional medicine system consists of several such natural products that 
have been used in ancient times and are also very popular today to treat a variety of 
dreadful diseases.   
Natural chemicals are gaining increased limelight in the field of cancer research, due 
to their increased bioavailability and non-harmful nature. Biochemical level to 
understand their exact mechanism of action, of several such natural chemicals is 
under investigations, which are proving to be promising. One such naturally- 
derived compound is Embelin. 
Embelin is a type of benzo-quinone that is derived from the fruits of an Indian 
herbal plant known as Embelia ribes burm. The fruits of this plant are known to 
variety of therapeutic activity. Therefore, as Embelin is the active component from 
the fruits of this plant, it has so far seen to have anti-helmenthic, anti-diabetic, anti-
inflammatory, analgesic, immuno-modulatory activities. Based on its immense 
health benefits, the effect of Embelin on cancer cells was studied. 
The anti-cancer effect of Embelin was mainly studied upon breast cancer cells in-
vitro, since breast cancer is one of most fatal cancer accounting for the maximum 
number for cancer related deaths among women. 
In this chapter, we show that Embelin has potential anti-cancer properties, which can 
prove very beneficial. Embelin was seen to reduce the cancer cell proliferation, 
making it a useful and promising compound in halting the cancer progression.  
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Materials and Methods 
 
 
Cells, Drugs and Cell Culture 
 
The breast cancer cells studied were: MCF-7 and MDA-MB-231. Human Breast 
Carcinoma – MCF-7 (Adenocarcinoma), MDA-MB-231 (Adenocarcinoma) were 
purchased from Japanese Collection of Research Bioresources (JCRB, Japan) 
Cell Bank. To understand the effect of Embelin on the process of metastasis, we 
used highly metastatic breast cancer cell lines. For this work, Mortalin over-
expressing highly metastatic cell lines were used. These stable Mortalin 
overexpressing metastatic derivatives were obtained by retro-viral transfections 
as described earlier (Wadhwa et al) [27,28].  MCF-7 and MDA-MB-231 were 
cultured in the DMEM (Dulbecco’s Modified Eagle Medium) (Life Technologies, 
CA) that was supplemented with 10% FBS (fetal bovine serum) at 37 °C, in a 
humidified incubator (5% CO2 and 95% air).  
Embelin was obtained purified from Sigma Aldrich Co., Japan. Embelin stocks 
were then, made by dissolving the adequate amount of it in dimethyl sulfoxide 
(DMSO) to obtain 1 mM stocks. These 1 mM stocks were aliquoted into tubes 
and were preserved at -20°C for further use. Concentrations were made by 
diluting the 1mM Embelin stock to the complete cell culture medium (DMEM) 
that was used for each experiment. All biochemical and imaging assays were 
performed at sub-confluent (60–70%) cultures.   
 
Cytotoxicity and Growth Inhibition Assay 
 
 
To determine the cytotoxic effect of Embelin on Human Breast cancer cell lines, 
an in-vitro cell viability experiment was performed. The effect of Embelin on 
cancer cell survival ability was determined using the MTT assay (Sigma Aldrich, 
Japan).  Cells initially cultured in 10-cm dish were trypsinized and harvested. 
These cells were then counted using a cell counter and the cells were  
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then diluted accordingly to reach a desired cell number for plating. An estimated 
equal number of cells were plated in each well. A Cell number of 5 × 10
3 
cells/well was plated in 96-well cell culture dishes. Following 24h, cells were 
supplemented with increasing concentrations of Embelin for an incubation 
period of about 48h or an incubation period as indicated. After the completion of 
the determined incubation period the cell viability was assessed. Cell viability 
was studied by the degree of conversion of yellow MTT by mitochondrial 
dehydrogenases of living cells to purple formazan. A working concentration of 
MTT (0.5 mg/mL) was supplemented to the cell culture medium for an 
incubation period of 4h following the treatment of cells as indicated. MTT- 
containing medium was aspirated and 100µL DMSO was added to each well to 
completely dissolve formazan crystals. The results were recorded at an 
absorbance of 550 nanometer using a multiwall plate reader by Tecan, 
Switzerland. Absorbance values was recorded from 3 individual experiments and 
analyzed. The P-value was estimated using by t-test calculator (GraphPad 
Software, Inc., CA). 
 
 
Morphological observations 
 
 
For understanding the affect of Embelin on cancer cells, a morphology 
examination experiment was performed. In this experiment, the cells were plated 
to 60-70% confluency in 6-well dishes and following the completion of 24h; the 
cells were treated with Embelin. Morphological study cells in treatment and non-
treatment groups was performed at intervals of every 24h for 4 days using a  
phase contrast microscope.  
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Colony forming assays 
 
 
 To understand the efficiency of Embelin to reduce cell transformation ability and 
the capability of a single cancer cell to multiply and generate its clones, a colony 
formation study was performed. For this experiment, cells initially being cultured 
in 10-cm dish were trypsinized and harvested. The cells were then, counted and 
an estimated number of 500 cells were plated per well of a 6-well dish. 
Following 24h, the cells were supplemented with medium containing Embelin. 
The culture plate was then incubated to multiply and form colonies for the next 
10 – 15 days, with a regular change in media every alternate day. When colonies 
were formed, they were washed 2-3 times with 1X PBS, followed by fixing with 
cold methanol for 10-15 minutes. Followed by fixing with methanol, the cell 
colonies were stained using 0.1% crystal violet for overnight. The stain was 
rinsed with water to remove all excess stain, dried and photographed. The 
number of colonies in each well was counted and analyzed. 
Data recorded from 3 independent experiments were analyzed, and the P-value 
were calculated by t-test calculator (GraphPad Software, Inc., CA). 
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Results 
 
 
Embelin is efficient in decreasing the cell viability of breast cancer cells and 
their highly metastatic derivatives.  
 
To understand the anti-cancer potential of Embelin, this is a quinone derivative from 
the fruit of Embelia ribes Burm. f., its effect on the cell viability of Human Breast 
cancer cells was analyzed. Embelin was seen to reduce the percentage cell viability 
of both MCF7 and MDA-MB-231 cells with increase in concentration. 
A clear decline in the percentage cell survival efficiency was observed in the cells 
with response to increasing concentration of Embelin. (Figure 3-1 A, B) 
Moreover, as failure to effect metastatic cancer cells leads to be the main reason for 
the failure of maximum anti-cancer drugs, therefore, the effect of Embelin on highly 
metastatic derivatives of these breast cancer cells were developed and tested for the 
anti-cancer effectiveness of Embelin. These highly metastatic derivatives of cancer 
cells was developed by inducing stable over-expression of Mortalin, an Heat shock 
family protein in the cells. Over the past several years of research in our lab, it has 
been established that mortalin over-expression in cells leads to increase in the 
hallmarks of cancer, and a reverse of down-regulation can lead to p53-mediated 
apoptosis causing the death of cancer cells. Therefore, targeting mortalin could 
prove as a promising anti-cancer therapy. 
25 
Based on these understandings, highly metastatic derivatives of MCF7 and MDA-
MB-231 were tested for the effectiveness of Embelin.  
Embelin induced similar anti-proliferative response in these cells, depicting that 
Embelin may proof beneficial in effecting both cancer cells and the metastatic 
cancer cells. (Figure 3-2 A, B) 
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Morphologically non- Cytotoxic low doses of Embelin reduce the division 
efficiency in breast cancer cells 
 
To understand the effectiveness of non-cytotoxic low doses of Embelin on cancer 
cells, a morphology analysis was performed. When the cells were treated with non – 
cytotoxic concentrations of Embelin, the division ability of cancer cells was reduced. 
However, there was no cell death seen. On analyzing the cells morphologically, the 
cells seemed healthy, but their growth or the rapid cell division was greatly reduced 
in comparison to untreated cells with Embelin. This similar response was seen in 
both the cancer cell lines, that is, MCF7 and MDA-MB-231, showing that the low 
concentration treatment of Embelin to cancer cells lead them to a growth arrest 
response.  (Figure 3-3 A, B; 3-4 A, B)  Also, a similar growth arrest response was 
observed in highly metastatic derivatives of cancer cells. (Figure 3-5, 3-6)   
 
 
Embelin halts the ability of a single cell to divide and generate its clones 
 
We next determined the efficiency of Embelin to inhibit or reduce the ability of a 
single cancer cell to divide and generate its clones. Upon completion of 
experimentation, Embelin showed significant reduction in the colony forming ability. 
The ability in cells that were supplemented with Embelin was reduced upto almost 
80% when compared to the control. Moreover, similar decrease was seen in both the 
breast cancer cell lines, MCF7 and MDA-MB-231. (Figure 3-7 A, B; 3-8 A, B)   
We next checked Embelin against highly metastatic mortalin over-expressing 
derivatives of cancer cells, where we observed similar inhibitory effect of Embelin 
on the colony formation ability of cells. (Figure 3-9 A, B; 3-10 A, B)   
The difference between the control and Embelin treated cancer cells was very 
significant, showing that Embelin can be a promising potential candidate as an anti-
cancer drug. 
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Discussions 
 
 
Cancer is a disease that accounts for millions of deaths worldwide every year.  
Despite various treatment options, the recurrence of cancer in patients has been the 
main cause of cancer related deaths.  
Moreover, the popular treatment options that are available in the market, target on 
the killing of cancer cells, but by doing that they account for multiple side-effects as 
these drugs target every rapidly dividing cell in the patient’s body. 
Due to the harmful side-effects caused, therapies involving use of natural products is 
gaining insight. The use of natural products in ancient medicinal system has been 
well quoted, mainly due to its non-harmful nature and the high abundance of 
resources.   
Based on these prospects, we selected a compound called Embelin that is derived 
from the fruits of a plant called Embelia ribes burm. Embelin is the key component 
from the fruits of this plant, and has been known for its various therapeutic 
properties. 
In this chapter, we tested Embelin on breast cancer cells to check its anti-cancer 
potential.  
It was seen that Embelin possessed anti-cancer potential as it greatly reduced the 
cell viability of breast cancer cells. Since, the failure of the several current cancer 
treatment options reasons to their inability to target metastatic cancer cells, which in 
turn leads to relapse of cancer in the patients. Therefore, the effectiveness of 
Embelin was checked against highly metastatic derivatives of breast cancer cells 
where, similar reduction in the cell viability was observed. Upon understanding the 
cytotoxic effect of Embelin on breast cancer cells and also similar effect on highly 
metastatic derivatives of breast cancer cells, we next considered to analyze the non-
cytotoxic dose of Embelin.  
As there are several key proteins that are involved in the functioning of both cancer 
and normal cells. Biochemically, the overexpression or the abundance of these 
proteins leads to uncontrollable division of cancer cells. Therefore, cytotoxic dose of  
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a product can also be responsible for targeting similar biomolecules also 
in the normal cells. So, based on this assumption and with the idea of developing a 
drug for cancer that is not lethal to the normal cells, we therefore, thought to study 
the effects of the non-cytotoxic dose of Embelin, for our further study. 
The understanding of the effect of non-cytotoxic dose of Embelin on breast cancer 
cell by their morphology study was then taken up next for analyses. 
Morphologically, It was observed that Embelin halts the multiplication of cells, 
showing a growth arrest response, leading to a clear decline in the population 
doubling efficiency of breast cancer cells. 
Moreover, the non-cytotoxic dose of Embelin was found to also be capable of 
reducing the efficiency of single cells to generate its clones.  
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6.  CHAPTER IV 
 
 
 
 
 
Embelin exhibits Anti - metastatic 
potential 
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Abstract 
 
 
Cancer is a dangerous disease, for which research everyday is extending hands, to 
find a suitable cure. Today, understanding the disease and its functioning has 
become a prime area of research which can help solve the mystery and give the 
patients suffering with this deadly disease a new life. Side effects from the 
conventional drugs add to another harmful dimension in the cancer treatment.  
Based on these observations and statistics, more and more focus is moving to natural 
compounds that can be used as an anti-cancer drug.  
In this study, I have selected one such plant derived compound, Embelin that is the 
active component from the fruits of a plant, Embelia ribes burm. In the earlier 
chapter, Embelin was investigated for its anti-cancer potential. Embelin exhibited 
very promising anti-proliferative activity, where it showed a remarkable significant 
decline in the cell viability with increasing concentration. To avoid any cytotoxic 
effect to normal cells, we selected a non-cytotoxic low dose, for our further study. At 
low concentrations also, Embelin significantly reduced the proliferation ability of 
cancer cells and also caused significant reduction in the colony forming efficiency 
of cancer cells. 
The availability of treatment options is constantly increasing, but sadly to give only 
a time-bound relief to most of the patients. The key reason for the failure: the spread 
of cancer. This is because the conventional medicines or treatment therapies 
practiced against cancer fail to target any metastatic or migrating cancer cells. This 
leads to the relapse of cancer. Therefore, targeting metastatic cells along with cancer 
cells is the most crucial part. 
With the understanding of this critical aspect of targeting the metastatic cells, in this 
chapter we investigated the Anti-metastatic potential of Embelin. 
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Introduction 
 
 
Cancer is a disease for which solutions are being searched every day. Besides 
this, cancer still targets a huge number of people worldwide, every year and the 
statistics seem to keep increasing.  
One possible reason for the increasing statistics is, the time of detection of cancer. 
By the time cancer is detected, it is no more in its preliminary stage and has 
already advanced far more than can be controlled. This means that the cancer has 
already metastasized or started spreading to other parts of the patient’s body.  
Metastasis is a highly complicated procedure in the progression and spread of 
cancer. In order to efficiently invade another location, a cancer cell needs to go 
through multi-step procedure, which include separating from the primary tumor 
by invading through the surrounding tissues and basement membranes, survival 
in the circulation to reach to distant organs and develop secondary tumors.
38 
Therefore, by the time a patient is diagnosed with cancer and the starts receiving 
anti-cancer medications, the disease is far more invasive to be controlled. This 
leaves the patient with very less positive hope, and accounts for the increasing 
statistics. The prime question to address lies in the effectiveness of the anti-
cancer drugs. Meanwhile, the most effective anti-cancer drugs do their best to 
stop cancer, but their main mode of action lies onto killing the cancer cells. On 
one hand, these drugs target every rapidly diving cancer cells, leaving the patient 
with a multiple varieties of side effects to be tolerated. Whereas, on the other 
hand, these drugs are incapable of targeting metastatic cells, leading to relapse of 
cancer.  
Understanding the importance of targeting metastatic cancer cells, in this chapter, 
we investigated the anti-metastatic potential of Embelin. 
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Materials and Methods 
 
 
Cells, Drugs and Cell Culture 
 
The breast cancer cells studied were: MCF-7 and MDA-MB-231. Human Breast 
Carcinoma – MCF-7 (Adenocarcinoma), MDA-MB-231 (Adenocarcinoma) were 
purchased from Japanese Collection of Research Bioresources (JCRB, Japan) 
Cell Bank. MCF-7 and MDA-MB-231 were cultured in the DMEM (Dulbecco’s 
Modified Eagle Medium) (Life Technologies, CA) that was supplemented with 
10% FBS (fetal bovine serum) at 37 °C, in a humidified incubator (5% CO2 and 
95% air).  
Embelin was obtained purified from Sigma Aldrich Co., Japan. Embelin stocks 
were then, made by dissolving the adequate amount of it in dimethyl sulfoxide 
(DMSO) to obtain 1 mM stocks. These 1 mM stocks were aliquoted into tubes 
and were preserved at -20°C for further use. Concentrations were made by 
diluting the 1mM Embelin stock to the complete cell culture medium (DMEM) 
that was used for each experiment. All biochemical and imaging assays were 
performed at sub-confluent (60–70%) cultures.   
 
Wound scratch assay 
 
To analyze the effect of Embelin on metastasis, the in vitro cancer cell migration 
ability in control and Embelin treatment, was studied utilizing Wound-scratch 
assay. Cell growing in 10-cm dish were trypsinized and seeded in 6-well culture 
dish. The cells were cultured until, in a monolayer.  This monolayer was then 
wounded by uniformly damaging cells in a straight line using a pipette tip of 
200µl. Wound was rinsed using 1X PBS, 2-3 times, to wash away any partially 
attached cells, and then added with only medium and medium supplemented with 
Embelin in control and treated wells, respectively. The time of wounding was 
taken 0 h. The experimental dishes are then kept heal by covering the scratched 
surface. The efficiency of cancer cell migration was observed in the form of 
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pictures (after 24h) using a microscope at a magnification of 10X. The results 
were analyzed using Wimsratch software (Wimasis Image Analysis, Germany).  
 
In vitro cancer cell chemotaxis assay 
 
To understand the effect of Embelin on in – vitro cancer cell invasion ability, an 
in – vitro chemotaxis assay was done. For this experiment, the cells that were 
initially being cultured in 10-cm dish were washed with PBS, and replated in 
matrigel invasion chambers from BD Biosciences at a cell number of 50,000 
cell/ml. These chambers were then in control and treatment groups, incubated in 
a humidified CO2 incubator for 20h. After the completion of the incubation 
period, invasion chambers were removed and stained. The stained membranes 
were washed for the removal of any excess stain, and allowed to dry at room 
temperature. The dried membranes were visualized under the microscope and 
pictured at a magnification of 10X. Migrated cells was dissolved using acetic 
acid dilution (10%) and results were quantitated using spectrophotometer at 
absorbance of 590 nanometer wavelength. 
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Results 
 
 
Embelin reduces the cancer cell migration ability 
 
 
To understand the anti-metastatic potential of Embelin, its inhibitory effect on the 
migration ability of breast cancer cells was investigated. For this purpose a wound 
scratch assay was performed. After wounding the cells in a straight line, cells in both 
control and Embelin treated well were allowed to migrate and heal the wound. After 
24h duration, it was observed that the wound in control well, where the cells were 
supplemented with only the culture media was almost coved with the migrated cells. 
However, in the wells where the cells were supplemented with Embelin containing, 
the wound was very slightly healed. Upon visual examination, similar results in both 
the cancer cells lines that is, MCF7 and MDA-MB-231 were observed. (Figure 4-1 
A; 4-2 A)  Further on, a comparative analysis of results in control and Embelin – 
treated wells was performed using Wimasis software and based on the quantitative 
values given by the software, a quantitative plot explaining the results was prepared. 
This resulting plot also gave similar results as seen by the wound scratch assay 
pictures. (Figure 4-1 B; 4-2 B)   
 
 
Embelin exhibits anti-invasive potential against cancer cells 
 
 
To understand the Anti-invasive potential of Embelin against breast cancer cells, an 
in-vitro chemotaxis assay was performed. The cells were seeded in a chemotaxis 
assay chambers and allowed to degrade the matrigel, that was coated onto a 
membrane and migrate to the other side of the membrane. The number of total cells 
that migrate through the membrane by degrading the matrigel tells the invasive 
potential present in the cells. More invasive cells degrade the matrigel - coated 
membrane faster and travel to the other side of the chamber that consists of  
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a chemo attractant (in this experiment FBS). Upon performing an invasion assay on 
control (non-treated) cells and the Embelin – treated cells, we observed the number 
of cells that were Embelin – treated showed significant reduction in their invasion 
ability, as compared to the control. (Figure 4-3 A; 4-4 A) More over, to confirm the 
results of visual examination, migrated cells were stained and extracted and their 
absorbance was measured. The results of plotted percentage absorbance explained a 
similar result on reduction in the cell invasion ability of cancer cells when they were 
treated with Embelin with respect to control. (Figure 4-3 B; 4-4 B) 
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Discussion  
 
 
Metastasis is the key step in the progression of cancer, and also the key reason for 
the failure of convention anti-cancer drugs. Because metastasis is such a complex 
process, it still remains to be completely understood. Therefore, drugs targeting the 
metastatic cells or reducing metastatic nature of cancer cells is greatly in demand.  
Since Embelin showed promising reduction in the cell viability of highly metastatic 
derivatives of cancer cells, we assumed that Embelin could also possibly reduce the 
metastatic properties of cancer cells. Based on this idea, we checked Embelin 
against the metastatic properties of breast cancer cells by investigating its effect on 
cancer cell migration and on cancer cell invasion ability. 
Migration of a cancer cell help it to travel through circulation, from the source of 
primary tumor to distant body parts, thus making it an essential process to be 
targeted by any anti-metastatic potential drug. Embelin exhibited strong response 
against cancer cell migration potential. Cancer cells that were treated with Embelin 
showed reduced migration ability with respect to control.  
Invasive property of a cancer cell helps the cancer cell to degrade and invade 
through the surrounding tissues and the basement membrane to come in contact with 
the circulation, lymphatics or the peritoneal space. This is a very important step in 
the process of metastasis, through which a cancer cell can render itself free and 
move to different other tissues in the body. We found that Embelin treated cancer 
cells exhibited reduced invasive potential as depicted by a reduced degradation of 
the matrigel coating on the membrane. This further leads to reduced migration of 
cells through the matrigel coated membrane. Whereas, the control cells exhibited 
enhanced invasive property and were seen to migrate effectively through the 
matrigel coated membrane. These results depict that Embelin shows promising anti-
metastatic potential against breast cancer cells. 
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7.  CHAPTER V 
 
 
 
 
Embelin targets Mortalin-p53 
interactions 
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Abstract 
 
This study was initiated with an idea of finding a better drug to target breast 
cancer, which would be less toxic to the patients and account for fewer side – 
effects, could also target disseminated cancer cells, besides targeting the primary 
tumor cells, and also, could overcome the barrier of chemo – resistance in cancer 
therapy.  
Based on all these ideas, we selected a plant derived compound, Embelin through 
our initial results of screening different anti – cancer drugs.  
Embelin is a type of benzo-quinone compound which is found in fruits of 
Embelia ribes Burm. f.(Primulaceae). Embelin has been reported to exhibit 
multiple therapeutic properties such as including Anthelmintic, Anti-Tumor, 
Anti-Diabetic, Anti-Bacterial and Anti-Inflammatory.  
Embelin was observed to reduce cancer cell proliferation, cancer cell migration 
and invasion. Embelin was also seen to reduce mortalin expression levels 
significantly during the initial screening of various anti-cancer drugs. Mortalin 
has been well documented to bind to tumor – suppressor protein, p53 and 
inactivate its tumor – suppressor functions.  
In this chapter, we investigate Embelin’s ability to disrupt mortalin – p53 binding 
in cancer cells. 
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Introduction 
 
Cancer stakes millions of lives worldwide, every year. An important criterion in 
the cancer treatment is the resistance developed by the cancer cells against the 
anti-cancer therapy.  
Heat shock proteins are generally expressed in a cell when they are in a state of 
stress. In the case of cancer, a cancer cell is abundant in the expression of heat 
shock proteins. These proteins protect the cell from any external stress, 
accounting for cell survival functions. The two heat shock family proteins that 
are first to be released in a cell are hsp70 and hsp27 family proteins. 
10
 
Mortalin is a heat – shock family 70 protein. Mortalin functions as a cell survival 
protein, by protecting the cancer cell from the stress generated by anti-cancer 
drugs. Mortalin is known to bind to p53, a tumor suppressor proteins and thus 
inactivate its tumor suppressor functions. In common case, a functional p53 goes 
to the nucleus and induces tumor suppressive functions in a cancer cell, by 
halting its division and executing apoptosis. However, when mortalin binds to 
p53, it holds it in the cytoplasm preventing its nuclear localization and thus, 
inactivating its tumor-suppressor function. 
16,32
 
In this chapter, since, we have earlier observed that Embelin is capable of 
reducing the cellular levels of mortalin. We assumed that it might be possible that 
Embelin could be potential in disrupting the mortalin-p53 interaction leading to a 
release of p53, which could thereby localize itself to the nucleus and perform its 
tumor-suppressor functions. 
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Materials and Methods 
 
Cells, Drugs and Cell Culture 
 
The breast cancer cells studied were: MCF-7 and MDA-MB-231. Human Breast 
Carcinoma – MCF-7 (Adenocarcinoma), MDA-MB-231 (Adenocarcinoma) were 
purchased from Japanese Collection of Research Bioresources (JCRB, Japan) 
Cell Bank. MCF-7 and MDA-MB-231 were cultured in the DMEM (Dulbecco’s 
Modified Eagle Medium) (Life Technologies, CA) that was supplemented with 
10% FBS (fetal bovine serum) at 37 °C, in a humidified incubator (5% CO2 and 
95% air).  
Embelin was obtained purified from Sigma Aldrich Co., Japan. Embelin stocks 
were then, made by dissolving the adequate amount of it in dimethyl sulfoxide 
(DMSO) to obtain 1 mM stocks. These 1 mM stocks were aliquoted into tubes 
and were preserved at -20°C for further use. Concentrations were made by 
diluting the 1mM Embelin stock to the complete cell culture medium (DMEM) 
that was used for each experiment. All biochemical and imaging assays were 
performed at sub-confluent (60–70%) cultures.   
 
Immunoblotting 
 
To identify the effect on expression level of proteins in effect to that of Embelin –
treatment, Immunoblotting technique was used. Cells that were priorly treated and 
not-treated with Embelin were prepared as protein lysates samples for loading in 
SDS – PAGE gels. Equal amounts of whole cell protein samples from control and 
treatment groups were seperated on 10% SDS-polyacrylamide gels, and transferred 
to PVDF membrane. The blots were incubated with the desired primary antibodies 
(Mortalin) followed by their respective secondary antibodies. Anti β-actin antibody 
was used as internal loading control. Quantitation of western blots was done by 
ImageJ software (NIH, MA). 
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Immuno – cytochemical staining 
 
For immuno - fluorescence or immuno – cytochemical staining, cells were 
cultured in 12-well dish containing coverslips. Control and cells from treatment 
groups were fixed, and stained with primary and secondary antibodies of interest 
for the study. In this study, antibodies for Mortalin and p53 were used. 
Coverslips containing stained cells, were mounted and observed using Carl Zeiss 
microscope (Axiovert 200 M). 
 
Luciferase reporter assay 
MCF-7 cells were plated in 6-well cell culture dish. Following overnight 
incubation, cells were then transfected with p53 - luciferase plasmid reporter, 
using X-tremeGENE 9 DNA Transfection Reagent. Control and treatment group 
cells, were kept for an incubation period of 48h. The cells were then used for 
studying the luciferase activity.  
Quantitative Real – Time Polymerase Chain Reaction (qRT-PCR) 
 
To estimate the modulation at the mRNA level, quantitative Reverse 
Transcriptase PCR (qRT-PCR) was done. Total RNA extracted was reverse 
transcribed to cDNA, The resultant cDNA was subjected to amplification using 
gene specific primers. The analysis of the results was done using the relative 
analysis method of gene expression by the 2
- Δ ΔC
T method, as described by 
Kenneth J. Livak and Thomas D. Schmittgen 
41
 The gene specific primer 
sequences were as follows: 
 
Mortalin Sense 5′- AGCTGGAATGGCCTTAGTCAT-3′ 
Mortalin Antisense 5′- CAGGAGTTGGTAGTACCCAAATC -3′ 
MMP-9 Sense 5′-TGTACCGCTATGGTTACACTCG -3′ 
MMP-9 Antisense 5′- GGCAGGGACAGTTGCTTCT -3′ 
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MMP-3 Sense 5′- CTGGACTCCCGACACTCTGGA -3′ 
MMP-3 Antisense 5′- CAGGAAAGGTTCTGAAGTGACC-3′ 
18s  
(internal control) 
Sense 5′-CAGGGTTCGATTCCGTAGAG -3′ 
18s  
(internal control) 
Antisense 5′-CCTCCAGTGGATCCTCGTTA - 3′ 
 
Results 
 
Embelin reduces cellular Mortalin expression  
 
Mortalin is known to be over-expressed in cancer cells, which results in 
imparting the cancer cells with cell survival properties. We checked the effect on 
mortalin expression levels on cells upon treatment with Embelin. There was a 
reduction in the mortalin expression levels in the cells that were treated with 
Embelin, when compared to the cells that were not treated with Embelin. A 
similar response was observed in both the breast cancer cell lines, MCF7 and 
MDA-MB-231, as seen by the results of Immuno blotting and its quantitation 
and also by Immunofluorescence. (Figure 5-1 A, B; 5-2 A, B; 5-3, 4)  
 
 
Embelin causes down-regulation of Mortalin at the transcriptional level  
 
To understand whether this reduction of mortalin by Embelin is due to the down-
regulation of mortalin gene or only at the translational level, we performed 
quantitative Real time – polymerase chain reaction (qRT-PCR). Upon analysis of 
results, it was understood that this reduction of mortalin expression levels is 
mediated by its transcriptional down-regulation, showing that Embelin was 
responsible for down-regulation of mortalin at the transcriptional level. 
Embelin caused significant down-regulation of mortalin in both the breast cancer 
cell lines that is, in MCF7 and in MDA-MB-231 as seen in Figure 5-5, 5-6. 
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Reduction of mortalin by Embelin causes translocation of p53 to the 
nucleus 
 
To understand whether the down-regulation of mortalin by Embelin, is capable 
of rendering free p53 to the nucleus, the presence of nuclear p53 was 
investigated by Immunofluorescence. Embelin was seen to enhance the  
 
translocation of p53 to nucleus, predicatively by disrupting the binding of 
mortalin to p53 and thereby, activating its tumor-suppressor functions. (Figure 5-
7) A very similar result was also seen in p53-luciferese reporter assay. (Figure 5-
8) 
 
  
Embelin causes down-regulation of MMP.s at the transcriptional level 
 
As mortalin is known to enhance the invasive character of cancer cells, we next 
determined the status of Matrix Metalloproteinase in the cancer cells in response 
to presence and absence of Embelin treatment. Upon Embelin treatment, MMP-3 
and 9 were seen to be down regulated in cancer cells, as depicted by the 
quantitative real time polymerase chain reaction. (qRT-PCR) (Figure 5-9), which 
explains the inhibitory effect of Embelin against cancer cell invasion and cancer 
cell migration. 
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Discussion  
 
 
In the present study, we investigated the molecular mechanism of the effect of 
Embelin on Mortalin. As mortalin is a heat shock protein, it has been well 
documented for its cell survival properties, to protect the cancer cell, and 
therefore, making it a potential therapeutic target. 
Embelin showed reduction in the expression levels of mortalin in cancer cells. 
Moreover, similar effect was seen at the transcriptional level, where a significant 
down-regulation of mortalin was observed.  
Mortalin-p53 binding is response for the inactivation of the tumor-suppressor 
functions of the p53 protein. Disruption of this binding could render p53 free, 
which then translocate to the nucleus to execute its tumor suppressor functions. 
Embelin was seen to disrupt the mortalin-p53 interaction, as it’s down – 
regulation of mortalin led to nuclear localization of p53. 
Role of mortalin in enhancing cancer metastasis and invasion is well known, so 
an inhibitor would mortalin would also reduce the above properties. MMP are 
widely known for their ability to enhance invasive characteristics to a cancer cell, 
so the effect of MMP was checked in effect to Embelin treatment. Embelin down 
regulated the transcription of MMP.s, thus explaining the inhibitory effect of 
Embelin on cancer cell migration and cancer cell invasion. 
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8.  CHAPTER VI 
 
 
 
 
Embelin down regulates growth 
factors involved in cancer 
progression 
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Abstract 
 
 
Cancer accounts for millions of deaths worldwide. A search for a safe anti-cancer 
drugs is still in process. A wide degree of families and classes of proteins involved 
in cancer have been disclosed so far, depicting a blurred image of the complexity of 
this disease.  
In this study, we have tried to target some of the main hallmarks of cancer and some 
of the main hurdles that account for the failure of maximum anti-cancer drugs. In 
order to do this, we have used a plant – derived compound, Embelin for the entire 
study, based on the initial screening as an anti-mortalin molecule. 
In this chapter, we target the large variety of growth factors that are involved in the 
process of cancer and understand the effect on their expression levels with effect of 
Embelin.  
Growth factors are very critical in cancer progression, as a stimulated cancer cell 
begins to release a variety of growth inducing factors and also respond to the similar 
factors leading to the formation of an autocrine signaling mechanism, which leads to 
enhanced dis-regulation in proliferation signal, indicating the cell as cell for 
proliferation; in response to which the cell undergoes repetitive cycles of cell 
divisions. 
39
 
In the earlier chapters, we have witnessed that Embelin is capable of reducing 
percentage cell viability. And at lower dose, induce growth arrest (morphologically) 
and also reduce cell migration and cell invasion ability. 
So, in order to understand the molecular mechanism underlying into these effects, 
we next checked the changes in the expression levels of variety of growth factors 
involved in cancer. 
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Introduction 
 
 
It has been well quoted that the exposure of cancer cells to high levels of well-
known growth factors significantly increase the risks of colorectal, breast, and 
prostate cancer to name a few. 
Growth factors are proteins that are released from a cell. These proteins bind to 
their receptors present on the cell membrane, and this binding of the ligand and 
receptor leads to the initiation of a cascade of molecular events inside the cells, 
which leads to the expression of proteins that regulate cell proliferation. 
Therefore, the basic function of these growth factors is to enhance cell survival, 
to initiate proliferation and to enhance growth, as their name calls them, ‘growth 
factors’.  
However, a misbalance in these growth factors can lead to enhanced or 
uncontrollable growth in cells that is also regarded as uncontrollable cell division 
or multiplication in cells. 
39
 
This is a common phenomenon occurring in the case of cancer cells, where the 
loss of depency for specific growth factors and the cells begin to manufacture 
their own Growth Factor synthesis ("autocrine" activation), this is a case where a 
cell starts generation of its own growth factors and starts responding to the 
similar growth factors leading to an enhanced autocrine signaling. 
40
 
Based on these understandings, in this chapter, we investigated the mechanism of 
action of Embelin’s anti-proliferative and anti-metastatic effect by analyzing the 
expression levels of growth factors involved in cancer. 
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Materials and Methods 
 
Cells, Drugs and Cell Culture 
 
The breast cancer cells studied were: MCF-7 and MDA-MB-231. Human Breast 
Carcinoma – MCF-7 (Adenocarcinoma), MDA-MB-231 (Adenocarcinoma) were 
purchased from Japanese Collection of Research Bioresources (JCRB, Japan) 
Cell Bank. MCF-7 and MDA-MB-231 were cultured in the DMEM (Dulbecco’s 
Modified Eagle Medium) (Life Technologies, CA) that was supplemented with 
10% FBS (fetal bovine serum) at 37 °C, in a humidified incubator (5% CO2 and 
95% air).  
Embelin was obtained purified from Sigma Aldrich Co., Japan. Embelin stocks 
were then, made by dissolving the adequate amount of it in dimethyl sulfoxide 
(DMSO) to obtain 1 mM stocks. These 1 mM stocks were aliquoted into tubes 
and were preserved at -20°C for further use. Concentrations were made by 
diluting the 1mM Embelin stock to the complete cell culture medium (DMEM) 
that was used for each experiment. All biochemical and imaging assays were 
performed at sub-confluent (60–70%) cultures.   
 
Growth factors membrane array 
 
 
For understanding the regulation of growth factors involved in cancer in 
response to absence and presence of Embelin, a human growth factor 
membrane array experiment was performed. Initially, the cells were 
cultured in 10-cm dish. Following overnight incubation, the cells were 
either supplemented with only medium or treated with Embelin for the next 
48h. After completion of the incubation period, the culture media was 
harvested, to be used for the experiment. This culture media was 
centrifuged at full speed for 3 min.s to remove off any debris or cells. After 
centrifugation, the supernatant was harvested and used for the experiment.  
For the membrane array experiment, the Human Growth Factor Antibody 
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Array kit – membrane by Abcam, Cambridge, UK was used, and the 
experiment was performed using manufacturer’s guidelines. Briefly, each 
membrane was priorly blocked for 30 min.s at Room Temperature, following 
this; the membranes were incubated with the samples (cell culture supernatant) 
for 2h at the RT. The samples were then aspirated and the membranes were 
washed using the supplied washing buffers. Following this, the membranes were 
incubated with 1X Biotin-conjugated Anti-cytokines for 2h at RT. After the 
completion of the incubation, 1X Biotin-conjugated Anti-cytokines were 
aspirated and the membranes were washed as earlier. Then, 1X HRP-Conjugated 
Streptavidin was supplemented to each membrane – containing well containing a 
membrane and incubated for 2h at RT. Following the incubation time, the 
membranes were again washed using the washing buffer and then, visualized 
using chemiluminescence detection. The exposure images were recorded and the 
pixel calculation was done using ImageJ software (NIH).  The interpretation of 
the results was performed acc. to the manufacturer’s instructions. 
 
 
Quantitative Real – Time Polymerase Chain Reaction (qRT-PCR) 
 
To estimate the modulation at the mRNA level, quantitative Reverse 
Transcriptase PCR (qRT-PCR) was done. Total RNA extracted was reverse 
transcribed to cDNA, The resultant cDNA was subjected to amplification using 
gene specific primers. The analysis of the results was done using the relative 
analysis method of gene expression by the 2
- Δ ΔC
T method, as described by 
Kenneth J. Livak and Thomas D. Schmittgen 
41
 The gene specific primer 
sequences were as follows: 
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TGF-β Sense 5′- CAATTCCTGGCGATACCTCAG-3′ 
TGF-β Antisense 5′- GCACAACTCCGGTGACATCAA-3′ 
Wnt3a Sense 5′- CAAGATTGGATCCAGGAGT -3′ 
Wnt3a Antisense 5′- TCCCTGGTAGCTTTGTCCAG-3′ 
β-catenin Sense 5′- AAAGCGGCTGTTAGTCACTGG -3′ 
β-catenin Antisense 5′- GACTTGGGAGGTATCCACATCC -3′ 
Vimentin Sense 5′- CCTTGAACGCAAAGTGGAATC-3′ 
Vimentin Antisense 5′- GACATGCTGTTCCTGAATCTGAG -3′ 
18s  
(internal control) 
Sense 5′-CAGGGTTCGATTCCGTAGAG -3′ 
18s  
(internal control) 
Antisense 5′-CCTCCAGTGGATCCTCGTTA - 3′ 
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Results 
 
Embelin reduces the secretion levels of growth factors involved in cancer 
progression 
 
To understand the mechanism of action of Embelin on cancer cells, we checked the 
expression status of various growth factors involved in cancer. Since, a majority of 
growth factors are secreted from the cells, therefore, their expression levels was 
analyzed by investigating the cell culture media. The cell culture media of both 
control and cells treated with Embelin was harvested and used for the assay. Upon 
analysis, it was indicated that out of 41 targets analyzed in the study, more than 15 
growth factors were seen to be down regulated upon action with Embelin. (Figure 6 
– 1)   
 
Reduction of TGF-β by Embelin is through transcriptional down - 
regulation 
 
Understanding the above results, we next checked the transcriptional status of these 
two genes. Upon quantitative Real time PCR analysis, it was observed that 
transcription of TGF-β was significantly down regulated in cells that were treated 
with Embelin when compared to those that were not treated with Embelin. Thus, 
explaining the enhanced decline in the secretion levels of TGF-β in the Embelin 
treated cells. (Figure 6 – 2, 6 – 3) 
 
Embelin reduces the process of Epithelial to Mesenchymal transition 
(EMT) by down-regulating Wnt, β-catenin and Vimentin 
 
Epithelial to Mesenchymal Transition (EMT) is basically a developmental 
process. However, now EMT has been known to enhance the process of 
metastasis, which involves invasion. 
60,61
 Cancer cells present in primary tumor 
lose their cell-cell binding causing an increase in invasive properties, which help 
them to break through the basement membrane. Moreover, Embelin induced 
down – regulation of TGF- β, which plays a prime role in epithelial to  
 
60 
 
 
mesenchymal Transition. Embelin was so far also seen to reduce the levels of 
MMP.s. Based on these observations, we thought it would be worthwhile to 
study the effects of Embelin of the process of Epithelial to Mesenchymal 
transition, a process that is so closely linked in the regulation of Metastasis. For 
this, we studied the effect of Embelin on the regulation of three key regulators of 
the EMT process, Wnt, β-catenin and Vimentin.  
The regulation of Wnt, β-catenin and Vimentin was investigated by quantitative 
real time PCR analysis. Embelin was seen to down – regulate, Wnt in the treated 
cells, when compared to the control. (Figure 6-4) To confirm the suppression in 
the process of EMT, we investigated the regulation of its down-stream regulators, 
β-catenin and Vimentin, which were also down regulated at the transcriptional 
level. (Figure 6-5, 6) 
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Discussion  
 
 
 
The role of Growth factors in cancer progression has been well stated now. One 
of the first lines of evidence associating cancer with soluble growth factors (GFs) 
emerged from studies performed in the 1950s, in the laboratory of Victor 
Hamburger, by two fellows, Rita Levi-Montalcini and Stanley Cohen.  
Growth factors are known to enhance cell proliferation and is said to be essential 
for the survival of any type of cells. However, the over-reception of ligands such 
as growth factors leads to initiation of increased or uncontrollable proliferation 
signaling in a cell. This leads to cells to divide in an uncontrollable manner, 
which is also a common case in cancer.
39
 
However, in most cases, the cells rely on other cells for receiving growth factors 
like signals. But, in the exceptional case of tumor cells, is it observed that the 
cells derived from human tumors, often secrete Growth Factors, which are 
responsible for self-stimulation (autocrine) of growth. 
Based on this speculations and understandings, the expression level of different 
growth factors involved in cancer was checked. Embelin was seen to significantly 
reduce levels of several growth factors at the secretion level. The regulation of the 
modulated factors was then checked at both translational and transcriptional level, 
where TGF-β was down regulated. Moreover, as TGF- β is significantly involved in 
EMT, we checked the regulation of other important regulators of EMT, Wnt, β-
catenin and Vimentin, which were also down regulated. 
These findings bring some light on the mechanism of anti-proliferatory and anti-
metastatic action of Embelin on cancer cells. 
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9.  CHAPTER VII 
 
 
 
 
 
TACE is a target of Embelin 
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Abstract and Introduction 
 
Embelin is type of benzo-quinone compound, commonly found in the fruits of 
Embelia ribes Burm. f. (Primulaceae). Embelin exhibits a variety of therapeutic 
properties such as Anti-Diabetic, Anti-Bacterial, Anti-Tumor, Anti-Inflammatory 
and  Anthelmintic.  
The anti-inflammatory response of Embelin is known to be mainly due to its 
inhibitory effect against tumor – necrosis factor – alpha. TACE is a key 
proteolytic enzyme that leads to generation of tumor-necrosis factor-alpha. 
Therefore, the study in this chapter was performed to check if there is an existing 
link between tumor necrosis factor alpha and TACE.  
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Materials and Methods 
 
Cells, Drugs and Cell Culture 
 
The breast cancer cells studied were: MCF-7 and MDA-MB-231. Human Breast 
Carcinoma – MCF-7 (Adenocarcinoma), MDA-MB-231 (Adenocarcinoma) were 
purchased from Japanese Collection of Research Bioresources (JCRB, Japan) 
Cell Bank. MCF-7 and MDA-MB-231 were cultured in the DMEM (Dulbecco’s 
Modified Eagle Medium) (Life Technologies, CA) that was supplemented with 
10% FBS (fetal bovine serum) at 37 °C, in a humidified incubator (5% CO2 and 
95% air).  
Embelin was obtained purified from Sigma Aldrich Co., Japan. Embelin stocks 
were then, made by dissolving the adequate amount of it in dimethyl sulfoxide 
(DMSO) to obtain 1 mM stocks. These 1 mM stocks were aliquoted into tubes 
and were preserved at -20°C for further use. Concentrations were made by 
diluting the 1mM Embelin stock to the complete cell culture medium (DMEM) 
that was used for each experiment. All biochemical and imaging assays were 
performed at sub-confluent (60–70%) cultures.   
 
Immunoblotting 
 
To identify the effect on expression level of proteins in effect to that of Embelin –
treatment, Immunoblotting technique was used. Cells that were priorly treated and 
not-treated with Embelin were prepared as protein lysates samples for loading in 
SDS – PAGE gels. Equal amounts of  whole cell protein samples from control and 
treatment groups were seperated on 10% SDS-polyacrylamide gels, and transferred 
to PVDF membrane. The blots were incubated with the desired primary antibodies 
(TACE, MMP- 9, MMP- 2, VEGF) followed by their respective secondary 
antibodies. Anti β-actin antibody was used as internal loading control. Quantitation 
of western blots was done by ImageJ software (NIH, MA). 
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TACE activity assay 
 
In order to understand the effect of Embelin on cellular TACE activity, a TACE 
activity assay was performed. Cells in 6-well dish were plated at a concentration 
of 5 × 10
4
/well. Following overnight incubation, cells were incubated with 
Embelin for 24 h, and then, rinsed with 1X PBS. The cells were then used for 
studying the cellular TACE activity . 
 
 
TNF-α ELISA 
 
 
 
An Enzyme-Linked Immunosorbent Assay technique was used to estimate 
functional TNF-alpha levels, in control and Embelin – treated cells. Briefly, Cell 
suspension from cells with or without treated were tested for secreted tumor-
necrosis factor – alpha levels.  
 
RT-PCR (Reverse Transcriptase Polymerase Chain Reaction) 
 
To estimate the modulation at the mRNA level, Reverse Transcriptase PCR (RT-
PCR) was done. Total RNA extracted was reverse transcribed to cDNA, The 
resultant cDNA was subjected to amplification using gene specific primers. 
PCR products were separated on 1% agarose gel, which was visualized by Gel 
green staining. Pixel calculation of PCR results was done using with ImageJ and 
statistical analysis was done out using Student’s t test, where p values scores 
≤0.05 was considered significant. The gene specific primer sequences were as 
follows: 
 
TNF-α Sense 5′-GGAGAAGGGTGA CCGACTCA-3′ 
TNF-α Antisense 5′- CTGCCCAGACTCGGC AA-3′ 
TGF-α Sense 5′-CACACTCAGTTCTGCTTCCA-3′ 
TGF-α Antisense 5′-TCAGACCACTGTTTCTGAGTGGC- 3′ 
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AREG Sense 5′ GACCTCAATGACACCTACTCTGG- 3' 
AREG Antisense 5′-AAATATTCTTGCTGACATTTGC-3’ 
GAPDH 
(internal control) 
Sense 5′-ACCTGACCTGCCGTCTAGAA-3′ 
GAPDH 
(internal control) 
Antisense 5′-TCCACCACCCTGTTGCTGTA-3′ 
 
Immuno – cytochemical staining 
For immuno - fluorescence or immuno – cytochemical staining, cells were 
cultured in 12-well dish containing coverslips. Control and cells from treatment 
groups were fixed, and stained with primary and secondary antibodies of interest 
for the study. In this study, antibodies for Mortalin and p53 were used. 
Coverslips containing stained cells, were mounted and observed using Carl Zeiss 
microscope (Axiovert 200 M). 
 
 
Results 
 
Embelin reduces cellular TACE expression levels 
Embelin treatment to cancer cells was seen to significantly reduce cellular TACE 
expression levels as observed by experimental techiniques of western blotting 
and immuno-cytochemistry. (Figure 7-2) 
 
Embelin reduces TACE Activity 
For the next stage, effect of Embelin on TACE activity. Upon analysis, following 
Embelin treatment, a significant decline in TACE activity was observed. 
Moreover, Embelin at 20µM concentration showed even more significant effect 
than the commercially available TACE inhibitor. (Figure 7-3).  
 
Embelin treatment leads to reduction in TNF-α expression levels 
Furtheron, the resultant decline in TACE activity and cellular TACE levels by 
Embelin further led to significant decrease in TNF-α levels, as observed by TNF-
α ELISA. (Figure 7-4) 
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Embelin causes down-regulation of TACE at a translational level 
 
 
The decrease of TACE expression levels by Embelin was seen at only at 
translational level, as Embelin seemed to effect only yhe protein levels of TACE 
and not the mRNA levels of TACE. Morevoer, mRNA levels of  TACE 
downstream targets were also not affected. (Figure 7-5) 
 
 
 
Down-regulation of TACE does not directly effect the transcriptional 
activation of its down-stream targets  
 
We had learned so far that Embelin is capable of reducing the cellular TACE 
levels, which leads to decline in its functional activity and thereby, causing a 
reduction in the TNF-α levels. So, we wanted to investigate whether down-
regulation of TACE affected the transcriptional levels of its down-stream targets. 
Therefore, the mRNA level of TACE down-stream targets, TNF-α, TGF-α and 
AREG was checked using the technique of RT-PCR. However, no significant 
decrease in RNA levels was observed in Embelin - treated cells with compared to 
control, showing that there may be other factors responsible for maintaining the 
RNA levels of these genes or TACE levels do not affect their transcriptional 
levels directly. (Figure 7-6) 
 
Embelin down – regulates the expression levels of Matrix 
Metalloproteinases  
 
In light of this data, and as we have earlier witnessed the reduction of cell 
migration and cell invasion ability in the cancer cells, when they were treated 
with Embelin, as compared to control. We next examined the expression of 
metastatic markers that include Matrix Metalloproteinases. As Matrix 
Metalloproteinases are superiorly involved in enhancing the cancer cell invasion 
and cancer cell migration and Embelin treatment earlier significantly reduced 
cell invasion and cell migration ability. We next checked the expression levels of 
MMP proteins. Amongst the family of MMP proteins, MMP-2, MMP-9 in 
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control and treated cells was seen to show reduction (60% and 25% respectively) 
in their level of expression (Figure 7-7 A, B).  
 
Embelin reduces the expression levels of Vascular Endothelial growth 
factor (VEGF)  
Vascular endothelial growth factor (VEGF) is a signal protein. When it is 
produced, it stimulates vasculogenesis and angiogenesis. When VEGF is 
overexpressed in cancer cells, it can help the tumors by contributing in creating 
new blood vessels, leading to enhanced nutrient supply to tumors. This will help 
them the tumors to metastasize. Understanding the contribution of VEGF in 
cancer development and metastasis, we examined the expression of VEGF in 
control and treated cells and found reduction of about 48% in their level of 
expression (Figure 7-8 A, B).  
 
Embelin decreases the expression levels of hnRNP-K 
Heterogeneous nuclear ribonucleoprotein – K (hnRNP-K) is a protein that has 
widely been studied in our lab, and is known to contribute to metastasis in cancer. 
We, next, examined the expression status of an upstream regulator, hnRNP-K 
that has also been shown to play critical role in cell migration. We found that in 
response to Embelin treatment there was a significant reduction in hnRNP-K 
(Figure 7-9 A, B, Figure 7-10), supporting its potency for treatment of metastatic 
cancer. 
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Discussion  
 
 
In this chapter, I have found that Embelin exhibits inhibitory effect on TACE and 
multiple related proteins in the TACE involved pathway. An initial molecular 
dynamic study was performed, which showed that Embelin docks strongly into 
the active site of TACE, thereby, avoiding any other ligand to bind to its active 
site. The active site of TACE contains a zinc atom, coordinated by a zinc – 
binding motif. This complex of Embelin and TACE seemed very stable soon 
after 6ns of interaction. Molecular interactions with histidine and glutamate 
residues was observed which are known to play a significant role in managing 
the proteolytic functioning of TACE. 
Further with this biochemical effect of Embelin was studied on human breast 
cancer cell lines. Following the biochemical analysis, Embelin was seen to 
reduce cellular TACE expression levels. This reduction in cellular TACE 
expression levels and in its activity by Embelin led to an enhanced decline in the 
cellular TNF-alpha expression levels. However, upon observing the mRNA 
levels of TACE down – stream targets, TNF-alpha, TGF-alpha and Amphiregulin, 
Embelin was not seen to affect their mRNA levels.  
Moreover, expression levels of MMP-2 and MMP-9 proteins were seen to be 
down-regulated in cancer cells that were treated with Embelin as compared to 
that of their control counter –parts.  Further on, hnRNP-K, which is known to be 
primly involved in enhancing the process of metastasis, and VEGF 
57-59
, an 
angiogenesis factor, was also observed to decrease in Embelin – treated cells 
when compared to control.   
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Conclusions & Future works 
 
 
Cancer is a deadly disease. It accounts for millions of deaths worldwide. Finding 
a suitable drug for cancer is one of the major missions of cancer research.  
Breast cancer is the second leading cause of deaths from cancer amongst women. 
The therapies available provide a temporary relief to the patients, which mainly 
target on the removal of a part of the tissue or the complete removal. However, 
the main problem arises when despite the removal of the primary tumor, the 
patient begins to witness the secondary tumors in other parts of the body. 
Chemotherapy comes to rescue for the patient in such circumstances. 
However, chemotherapy targets the cancer by killing the cancer cells in the body, 
but in such a condition it also begins to target many other rapidly dividing cells 
in the patients’ body, accounting for multiple side effects, suppressed immune 
response and along with failure to target highly invasive cancer cell that have 
been disseminated from the primary tumor. 
Another problem arises when the prolonged exposure to chemotherapy, makes 
the cancer cells in a patient chemo – resistant. Failure to kill the cancer cells by 
extended chemotherapy along with multiple side – effects and occurrence of 
multiple tumors overall worsens the situation. 
Based on these understandings, this study started with the idea for developing a 
potential anti-cancer drug that could possibly target the following criteria during 
its treatment mechanism: 
 New candidate that would be better than the current conventional drugs. 
 It would be safe to the patient and would not be an inducer of several toxic 
side effects. 
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 It could target both cancer cells in the primary tumor as well as the 
metastatic cancer cells that have been disseminated or are in the process of 
dissemination. 
 It could over come the barrier of chemo resistance by targeting the heat 
shock family proteins that are specifically known to enhance cell survival 
ability by inducing chemo resistance. 
 And, finally, to study the mechanism of action of such an anti-cancer 
potential drug. 
Based on the above criteria, we initially screened multiple convention anti-
cancer drugs and two nature derived compounds for their anti-mortalin 
potential. Based upon the screening results, Embelin was selected for the 
further study. 
Embelin was seen to reduce the breast cancer cell proliferation with increasing 
dose. On analyzing the effect of its action, it was observed that Embelin 
induced growth arrest response in the cancer cells, at lower concentrations. 
Moreover, Embelin was also seen to reduce colony-forming ability in cancer 
cells, explain its anti-cancer potential. 
Since, failure to effect the metastatic cancer cells accounts for the 
ineffectiveness of maximum anti-cancer drugs, so the anti-metastatic potential 
of Embelin was investigated, where Embelin reduced cancer cell migration and 
cancer cell invasion.  
To understand the mechanism of action of Embelin, its effect on growth factors 
was analyzed where Embelin reduced expression levels of various growth 
factors. Moreover, TGF-β was also down regulated at the transcriptional level. 
Moreover, as TNF-α is key protein in the process of cancer and inflammation, 
Embelin’s effect on it was studied. TACE is known to release the soluble active 
form of TNF-α, therefore, TACE is considered a key therapeutic target in 
inflammation and cancer. Embelin reduced expression levels of TACE, which 
further led to a decline in the shedding activity of TACE, thus reducing the 
release of active TNF-α. A reduction in the levels of proteins involved in 
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angiogenesis, VEGF, and metastasis, MMP.s and hnRNP-K was also seen. 
As in the start of this project seen, that Embelin was capable of reducing the 
expression levels of Mortalin. We investigated if this reduction at the 
transcriptional level, where Embelin was observed to significantly reduce the 
transcription of Mortalin. Moreover, Embelin also disrupted the Mortalin-p53 
interaction, as observed by translocation of p53 to the nucleus. 
As Epithelial to Mesenchymal transition (EMT) is an important step in the 
process of metastasis. The importance of Wnt signaling is well known in the 
process of EMT, therefore, the effect of Embelin on this signaling was observed. 
Embelin was seen to reduce the Wnt 3a. Followed by this its, downstream 
genes, β-catenin and Vimentin were also down regulated by Embelin. 
Through the above observations, we understand that Embelin is a promising anti-
cancer compound. And, with further investigation in its anti – cancer potential, 
this compound can be a very useful Bioindustrial product anti-cancer drugs. 
Since, Embelin is of plant origin, it is non – harmful, a criteria very important for 
the selection of various anti-cancer drugs. Moreover, this study started with 
Embelin’s selection by assessing its anti-mortalin ability.  Embelin also showed 
inhibitory effect against metastasis by targeting some key molecules involved in 
cancer. 
We therefore propose Embelin as a promising Bioindustrial anti cancer 
compound, which requires further study. 
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